Multiple System Atrophy (MSA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by autonomic failure (cardiovascular and urinary dysfunction), parkinsonism, cerebellar impairment, and corticospinal signs. The etiology of MSA remains unknown, but its pathological hallmark features include the presence of α-synuclein aggregates primarily in oligodendroglia, accompanied by neurodegeneration in striatonigral and olivopontocerebellar structures. MSA typically emerges in adulthood, with an onset after age 30 and a mean age of onset ranging from 55 to 60 years. MSA’s Clinical manifestations include orthostatic hypotension, syncope, respiratory disturbances (including sleep apnea, stridor, and inspiratory sighs), constipation, early urinary incontinence, erectile dysfunction in males, and Raynaud syndrome. MSA can present in two main forms: MSA-p, characterized by predominant parkinsonian features including bradykinesia, rigidity, irregular jerky postural tremor, and abnormal postures (such as camptocormia, Pisa syndrome, and disproportionate antecollis); and MSA-c, characterized by predominant cerebellar features such as gait and limb ataxia, oculomotor dysfunction, and dysarthria. Unlike Parkinson’s disease, classic pill-rolling rest tremor is uncommon in MSA-p, and MSA-c should be differentiated from dominantly inherited spinocerebellar ataxias (SCAs 1, 2, 3, 6, and 7), fragile X-associated tremor/ataxia syndrome (FXTAS), and mitochondriopathies (POLG1 gene mutations). MSA is a rapidly progressive disease that leads to wheelchair dependence, unintelligible speech, intermittent urinary catheterization, disabling orthostatic hypotension, and cognitive impairment, particularly executive dysfunction. Disease progression can be assessed using the unified MSA rating scale (UMSARS), which evaluates daily life activities, autonomic and motor impairment, and overall disability.
• MSA is considered a rare condition in the United States, affecting an estimated 15,000 to 50,000 individuals, with a prevalence ranging from 3.4 to 4.9 cases per 100,000 population.

Thelansis’s “Multiple System Atrophy (MSA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Multiple System Atrophy (MSA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Multiple System Atrophy (MSA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Multiple System Atrophy (MSA) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Multiple System Atrophy (MSA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Multiple System Atrophy (MSA), Multiple System Atrophy (MSA) market outlook, Multiple System Atrophy (MSA) competitive landscape, Multiple System Atrophy (MSA) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)